Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10672044 | 0.87 | GSTP1 (0.41) | GSTP1L3MBTL1NSD2ABL1PPARG | |
| SCHEMBL410523 | 0.86 | MRGPRX4 (0.41) | CYP2C19SMN1; SMN2RHEBNPC1CYP1A2 | |
| SCHEMBL9653085 | 0.85 | LOXL2 (0.48) | GSTP1L3MBTL1NSD2ABL1PPARG | |
| SCHEMBL9012908 | 0.85 | L3MBTL1 (0.43) | GSTP1L3MBTL1NSD2ABL1PPARG | |
| Hydrochloric Acid SCHEMBL10894906 | 0.84 | L3MBTL1 (0.42) | GSTP1L3MBTL1NSD2ABL1PPARG | |
| SCHEMBL106114 | 0.83 | NPC1 (0.43) | CYP2C19MAPTSMN1; SMN2POLBNPC1 | |
| SCHEMBL4145610 | 0.82 | ALDH1A1 (0.53) | L3MBTL1CYP2C19MAPTCYP2C9SMN1; SMN2 | |
| SCHEMBL13462058 | 0.82 | LMNA (0.50) | GSTP1L3MBTL1NSD2ABL1PPARG | |
| SCHEMBL9012870 | 0.82 | HTR2A (0.43) | L3MBTL1NSD2ABL1PPARGRIN1 | |
| SCHEMBL2116326 | 0.80 | L3MBTL1 (0.54) | GSTP1L3MBTL1NSD2ABL1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4298103-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022182861-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| EP-3606921-B1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2022-06-01 | — | — | EP | disclosed |
| EP-3606921-B1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2022-06-01 | — | — | EP | disclosed |
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-05-05 | — | — | US | disclosed |
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-05-05 | — | — | US | disclosed |
| EP-2906216-B1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-10633366-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-04-28 | — | — | US | disclosed |
| EP-0711282-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| US-5401734-A | MICROBIOCIDES | FUJISAWA PHAMACEUTICAL CO., LTD. (JP) | 1995-03-28 | — | — | US | disclosed |
| WO-1995004045-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| US-5244890-A | Treatment of infectious diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0243924-B1 | 2-OXO-1-(SUBSTITUTED PHOSPHOROUS)AZETIDINES | E.R. Squibb & Sons, Inc. (US) | 1992-12-23 | — | — | EP | disclosed |
| US-4743685-A | 2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines | E. R. SQUIBB & SONS, INC. (US) | 1988-05-10 | — | — | US | disclosed |
| US-4723002-A | 1-(substituted phosphorous)-azetidinone antibacterials | E. R. SQUIBB & SONS, INC. | 1988-02-02 | — | — | US | disclosed |
| EP-0243924-A2 | 2-Oxo-1-(substituted phosphorous)azetidines | E.R. Squibb & Sons, Inc. (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4632985-A | 3-acylamino-2-oxo-1-azetidinesulfonic acids | E. R. SQUIBB & SONS, INC. (US) | 1986-12-30 | — | — | US | disclosed |
| EP-0204207-A1 | 3-acylamino-2-oxo-1-azetidinesulfonic acids | E.R. Squibb & Sons, Inc. (US) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633366-B2 | Antibacterial compounds | MRPL21, LAS1L, MRPL19 | GSTP1 2180/4885L3MBTL1 527/4885NSD2 4652/4885 |
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BRAF, NRAS, RAF1 | GSTP1 2043/4885L3MBTL1 3450/4885NSD2 3449/4885 |
| US-10640488-B2 | Antibacterial compounds | MRPL21, CLPP, NRDC | GSTP1 908/4885L3MBTL1 2951/4885NSD2 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.